| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
32,605 |
2,799 |
$3.88M |
| A4657 |
Syringe, with or without needle, each |
2,726 |
1,761 |
$206K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
25,091 |
2,068 |
$24K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
34,156 |
2,364 |
$14K |
| J1756 |
Injection, iron sucrose, 1 mg |
7,299 |
1,770 |
$4K |
| 0250 |
|
180 |
24 |
$3K |
| 83970 |
|
1,294 |
1,189 |
$727.85 |
| 82728 |
|
1,059 |
986 |
$650.72 |
| 82306 |
|
513 |
471 |
$493.46 |
| 85041 |
|
1,595 |
1,446 |
$111.92 |
| 90662 |
|
49 |
48 |
$56.01 |
| 90674 |
|
113 |
108 |
$28.13 |
| 83550 |
|
1,082 |
999 |
$6.20 |
| 83540 |
|
1,089 |
1,006 |
$5.15 |
| 85048 |
|
1,554 |
1,408 |
$0.00 |
| 82108 |
|
80 |
67 |
$0.00 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
536 |
359 |
$0.00 |
| J0604 |
Cinacalcet, oral, 1 mg, (for esrd on dialysis) |
735 |
197 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
102 |
101 |
$0.00 |